Trials / Completed
CompletedNCT00111696
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
Phase I Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Advanced Malignant Melanoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MEDI-522 | Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2007-08-01
- Completion
- 2007-11-01
- First posted
- 2005-05-25
- Last updated
- 2012-03-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00111696. Inclusion in this directory is not an endorsement.